- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04471480
TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)
Paclitaxel and Carboplatin Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Esophageal Cancer(ESCC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400042
- Daping Hospital, Third Military Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients volunteered to participate in the study and signed the informed consent;
- Age 18-75, both male and female;
- Histologically or cytologically confirmed advanced or metastatic (stage IIIB, III C or IV) ESCC .
- At least one measurable lesion according to RECIST 1.1,which should not be treated locally, such as radiotherapy.
- ECOG PS 0-1- Page 3 of 5 [DRAFT] -
- Expected survival ≥ 3 months
- Patients who never received systemic therapy in the past, including radiotherapy ,chemotherapy, targeted therapy and immunotherapy , or patients who relapsed more than 6 months after adjuvant chemotherapy.
- The main organ functions accorded with the following criteria within 7 days before treatment:
(1)Blood routine examination ( without blood transfusion in 14 days): hemoglobin (HB) ≥ 90 g/L; neutrophil absolute value (ANC) ≥ 1.5 *109/L; platelet (PLT) ≥80 *109/L.
(2) Biochemical tests should meet the following criteria: 1) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); 2) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 *ULN, if accompanied by liver metastasis, ALT and AST ≤ 5* ULN; 3) serum creatinine (Cr) ≤ 1.5* ULN or creatinine clearance rate (CCr) ≥ 60 ml/min;4) Serum albumin (≥35g/L). (3) Doppler echocardiography: left ventricular ejection fraction (LVEF) ≥the low limit of normal value (50%).
9 Tissue samples should be provided for biomarker analysis (such as PD-L1 ) Patients who could not provide new tissues could provide 5-8 paraffin sections of 3-5 μm by archival preservation.
Exclusion Criteria:
- Severe allergic reactions to humanized antibodies or fusion proteins in the past
- known to have hypersensitivity to any component contained in Endostar or antibody preparations;
- Diagnosed of immunodeficiency or received systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 14 days before the study, allowing physiological doses of glucocorticoids (≤10mg/day prednisone or equivalent);
- Patients with active, known or suspected autoimmune diseases. Patients with type I diabetes, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment(such as vitiligo, psoriasis or alopecia). Patients who would not triggers can be included.
- Serious heart disease, include congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction, and severe valvular disease.
- Patients treated targeted drugs such as bevacizumab, sunitinib, sorafenib, imatinib, famitinib, regiffenil, apatinib and anlotinib
- Patients recieved systemic antineoplastic therapy, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or mitomycin C within 6 weeks before the grouping),recieved over-extended-field radiotherapy (EF-RT) within 4 weeks before the grouping or limited-field radiotherapy to evaluate the tumor lesions within 2 weeks before the grouping
- Positive hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus antibody (HCV Ab), indicating acute or chronic infection.
- Patients with active pulmonary tuberculosis (TB) infection judged by chest X-ray examination, sputum examination and clinical physical examination. Patients with active pulmonary tuberculosis infection in the previous year should be excluded even if they have been treated; Patients with active pulmonary tuberculosis infection more than a year ago should also be excluded unless the course and type of antituberculosis treatment previously were appropriate.
- Patients with brain metastases with symptoms or symptoms controlling less than 2 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: group A,TCCA
paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +anlotinib 10mg, PO, d1-14, q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab plus anlotinib for maintenance therapy until PD or intolerable toxicity
|
chemotherapy and immunotherapy plus antiangiogenic therapy
Other Names:
|
EXPERIMENTAL: group B,TCC
paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w +camrelizumab 200 mg, IV, d1, q3w, after the treatment for 4-6 cycles, camrelizumab for maintenance therapy until PD or intolerable toxicity
|
chemotherapy and immunotherapy plus antiangiogenic therapy
Other Names:
|
OTHER: group C,TC
paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w
|
chemotherapy and immunotherapy plus antiangiogenic therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival (OS)
Time Frame: approximately 36 months
|
overall survival is defined as the time from randomization to death from any cause
|
approximately 36 months
|
objective response rate(ORR)
Time Frame: approximately 18 months
|
complete response(CR)+partial response(PR) according to RECIST 1.1
|
approximately 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival(PFS)
Time Frame: approximately 36 months
|
progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause
|
approximately 36 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCAC-ESCC-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ESCC
-
Tianjin Medical University Cancer Institute and...RecruitingESCC | Adjuvant Treatment | Lymph Node Positive | PembrolizumabChina
-
Xijing HospitalRecruiting
-
LiuJunFengOrigiMedUnknownPrognosis of Patients With ESCCChina
-
China Medical University HospitalUnknownVEGFC Protein in Serum | VEGFC Protein in Non Small Cell Lung Cancer | VEGFC Protein in ESCC | CTTN Protein in ESCC | miR326 in ESCC and Non Small Cell Lung Cancer
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MFChina
-
Shanghai Henlius BiotechRecruitingESCC or Esophageal Adenosquamous CarcinomaChina
-
The First Affiliated Hospital of Xinxiang Medical...BeiGeneNot yet recruiting
-
BeiGeneCompletedEsophageal Squamous Cell Carcinoma (ESCC)Spain, United States, United Kingdom, China, Taiwan, Korea, Republic of, Japan, France, Germany, Belgium, Italy
-
National Health Research Institutes, TaiwanChina Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaboratorsEnrolling by invitationEsophageal Squamous Cell Carcinoma (ESCC)Taiwan
-
BeiGeneActive, not recruitingEsophageal Squamous Cell Carcinoma (ESCC)China
Clinical Trials on TC/PD-1 inhibitor/anlotinib
-
Xiaorong DongUnknown
-
Qingdao Central HospitalRecruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Adanate, IncRecruiting
-
Istari Oncology, Inc.Active, not recruiting
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Shanghai Chest HospitalRecruitingNon Small Cell Lung CancerChina
-
Canadian Cancer Trials GroupMelanoma and Skin Cancer Trials LimitedRecruitingUnresectable/Metastatic MelanomaCanada, Australia
-
Buzzard PharmaceuticalsBaylor Research InstituteRecruitingSolid Tumor, AdultUnited States
-
Sun Yat-sen UniversityRecruitingEndometrial CancerChina